Skip Navigation

Publication Detail

Title: Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.

Authors: Conway, Kathleen; Edmiston, Sharon N; Tse, Chiu-Kit; Bryant, Christopher; Kuan, Pei Fen; Hair, Brionna Y; Parrish, Eloise A; May, Ryan; Swift-Scanlan, Theresa

Published In Cancer Epidemiol Biomarkers Prev, (2015 Jun)

Abstract: African American (AA) women are diagnosed with more advanced breast cancers and have worse survival than white women, but a comprehensive understanding of the basis for this disparity remains unclear. Analysis of DNA methylation, an epigenetic mechanism that can regulate gene expression, could help to explain racial differences in breast tumor clinical biology and outcomes.DNA methylation was evaluated at 1,287 CpGs in the promoters of cancer-related genes in 517 breast tumors of AA (n = 216) or non-AA (n = 301) cases in the Carolina Breast Cancer Study (CBCS).Multivariable linear regression analysis of all tumors, controlling for age, menopausal status, stage, intrinsic subtype, and multiple comparisons [false discovery rate (FDR)], identified seven CpG probes that showed significant (adjusted P < 0.05) differential methylation between AAs and non-AAs. Stratified analyses detected an additional four CpG probes differing by race within hormone receptor-negative (HR(-)) tumors. Genes differentially methylated by race included DSC2, KCNK4, GSTM1, AXL, DNAJC15, HBII-52, TUSC3, and TES; the methylation state of several of these genes may be associated with worse survival in AAs. TCGA breast tumor data confirmed the differential methylation by race and negative correlations with expression for most of these genes. Several loci also showed racial differences in methylation in peripheral blood leukocytes (PBL) from CBCS cases, indicating that these variations were not necessarily tumor-specific.Racial differences in the methylation of cancer-related genes are detectable in both tumors and PBLs from breast cancer cases.Epigenetic variation could contribute to differences in breast tumor development and outcomes between AAs and non-AAs.

PubMed ID: 25809865 Exiting the NIEHS site

MeSH Terms: No MeSH terms associated with this publication

Back
to Top